{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:32Z","timestamp":1793659772525,"version":"4.5.1"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T00:00:00Z","timestamp":1274918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>Bendamustine is a cytotoxic agent with a novel mechanism of action. This phase I, dose\u2010escalation study evaluated the safety, tolerability, efficacy, and pharmacokinetics of bendamustine in Japanese patients with relapsed\/refractory indolent B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) or mantle cell lymphoma (MCL) without major organ dysfunction. Bendamustine 90 or 120\u2003mg\/m<jats:sup>2<\/jats:sup> (dose escalation) was administered intravenously over 60\u2003min on days 1 and 2 every 3\u2003weeks for up to three cycles. Nine patients (eight indolent B\u2010NHL and one MCL) received per\u2010protocol treatment, three at 90\u2003mg\/m<jats:sup>2<\/jats:sup> and six at 120\u2003mg\/m<jats:sup>2<\/jats:sup>. No dose\u2010limiting toxicities were observed; thus, the maximum\u2010tolerated dose was not reached. Grade 3\/4 hematologic toxicities were neutropenia (33%) and leukopenia (33%). Non\u2010hematologic toxicities were grade 1\/2 and included gastrointestinal events and fatigue. Peak plasma concentrations of bendamustine occurred near the end of infusion in both dose groups and were equivalent to therapeutic concentrations observed <jats:italic>in vitro<\/jats:italic>. Bendamustine was rapidly eliminated, with a mean elimination half\u2010life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>) of 29\u2003min. Plasma concentrations of active metabolites M3 and M4 were approximately 4 and &lt;1% of the plasma concentration of the parent molecule, with <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> of 42 and 33\u2003min, respectively. Two unconfirmed complete responses and six partial responses were observed for an overall response rate (ORR) of 89%. The recommended dose for this schedule in phase II trials is 120\u2003mg\/m<jats:sup>2<\/jats:sup>. The acceptable safety profile and high ORR warrant further investigation of bendamustine in relapsed or refractory indolent B\u2010NHL and MCL. (ClinicalTrials.gov ID: NCT00389051). (<jats:italic>Cancer Sci<\/jats:italic> 2010)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01633.x","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T06:54:41Z","timestamp":1274943281000},"page":"2054-2058","source":"Crossref","is-referenced-by-count":34,"title":["Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B\u2010cell non\u2010Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1111","volume":"101","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japanese Bendamustine Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,20]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_8_3_2","first-page":"1129","article-title":"SDX\u2010105 (bendamustine is a clinically active chemotherapeutic agent with a distinct mechanism of action","volume":"45","author":"Niemeyer CC","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0378-6"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the Stil (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel MJ","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603776"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3280149eb1"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00008463"},{"key":"e_1_2_8_14_2","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann MA","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0050-z"},{"key":"e_1_2_8_16_2","unstructured":"JaffeES HarrisNL SteinH VardimanJW eds.World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues 3rd edn. Geneva Switzerland:International Agency for Research on Cancer (IARC) Press;2001:119\u2013187."},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_8_19_2","volume-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","author":"Cancer Therapy Evaluation Program","year":"2006"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0331-5"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"},{"issue":"1","key":"e_1_2_8_23_2","first-page":"S54","article-title":"Population pharmacokinetics of bendamustine and metabolites in patients with indolent non\u2010Hodgkin lymphoma","volume":"83","author":"Owen JS","year":"2008","journal-title":"Pharmacol Ther"},{"key":"e_1_2_8_24_2","first-page":"458","article-title":"Pharmacokinetics of bendamustine in patients with malignant tumors","volume":"14","author":"Matthias M","year":"1995","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01633.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01633.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:11:48Z","timestamp":1697411508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01633.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,20]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01633.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01633.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,20]]}}}